Stockscreener 앱 받기
46.29
2.59%
-1.23
시간 외 거래:
46.60
0.31
+0.67%
전일 마감가:
$47.52
열려 있는:
$47.15
하루 거래량:
4.92M
Relative Volume:
2.25
시가총액:
$5.58B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-16.02
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
+28.87%
1개월 성능:
+58.26%
6개월 성능:
+32.56%
1년 성능:
+10.56%
1일 변동 폭
$45.18
$47.50
1주일 범위
$34.90
$48.32
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
46.29 | 5.82B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - TipRanks
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - TipRanks
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Avidity Biosciences Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
- Yahoo Finance
Biote Corp. shares fall 13.21% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences: What’s Fueling its Surge? - timothysykes.com
Small Biotech Catapults On Rumored Novartis Takeover - Investor's Business Daily
Biote Corp. shares fall 6.74% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Celcuity Inc. shares rise 3.71% intraday as Novartis considers deal for biotech Avidity Biosciences. - AInvest
Avidity soars after rumours of Novartis' takeout interest emerge - FirstWord Pharma
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium By Stocktwits - Investing.com India
Novartis Eyes Avidity Biosciences in Potential Takeover BidNews and Statistics - IndexBox
Novartis Weighing Takeover Bid for Avidity Biosciences - MarketScreener
Avidity Biosciences Stock Soars Amidst Breakthrough Therapy Designation - StocksToTrade
Avidity Biosciences (RNA) Surges 22.6% on Novartis Takeover Rumors: Is This the Catalyst for a Biotech Breakout? - AInvest
Avidity Biosciences rises on report of Novartis buyout deal - TradingView
Novartis makes takeover approach for Avidity Biosciences, FT reports - TipRanks
Avidity Biosciences stock soars on Novartis takeover approach report By Investing.com - Investing.com South Africa
Avidity Biosciences stock soars on Novartis takeover approach report - Investing.com
Novartis weighs deal for biotech Avidity to boost drug pipeline - Financial Times
Avidity Biosciences RNA 2025Q2 Earnings Preview Downside Ahead on Increased Clinical Trial Spending - AInvest
Avidity Biosciences’ chief legal officer sells $81k in stock - Investing.com
Avidity Biosciences’ chief legal officer sells $81k in stock By Investing.com - Investing.com Canada
Why Avidity Biosciences (RNA) Is Up 8.0% After FDA Breakthrough and Phase 3 Milestones in Rare Disease - simplywall.st
Daily Turnover | The turnover of Avidity Biosciences on 8/4 was $107.25 Million, Ranking 835 - AInvest
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - ADVFN Brasil
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):